Abstract

Long-acting insulins analogues are related with the reduction of hypoglycemic events.

Objective: Ultralong-acting insulin analog Degludec (IDeg) in type 1 diabetic patients (T1D) previously treated with Glargine (U-100) with severes hypoglycemic events and poor metabolic control.

Patients and Method: 230 T1D patients were followed for 18 months, average 34 years old and 14 years of the diabetes diagnosed. Hypoglycemias, biochemical parameters and insulin requirements were analyzed in a period of 18 months. All the patients were on a basal bolus regimen with IDeg as basal adjusted fortnightly, and ultra-fast bolus insulin pre-meals three times a daily.

Results: At 3 months fasting glycemia decreased from 253 mg/dl to 180 mg/dl; at 6 months 156 mg/dl; at 12 months151 mg/dl and at 18 months 150 mg/dl. Glycated hemoglobin (HbA1c) initially 10.6%, decreased at 3 months to 8.7% at 6 months 8.3% at 12 months 9.0%, at 18 months 9.0%. All these results were statistically significant p < 0.05. Hypoglycemic events, milds, moderate, severes, and nocturnal, decreased significantly throughout the study, improving the quality of life of patients

Conclusion: IDeg in T1D showed to reduce fasting glycemia, HbA1c, and hypoglycemic events.

 Keywords: Clinical Parameters; Fasting Glycemia; Metabolic Control

References

1. Simó R. “Nueva insulina basal de acción ultralenta: insulina degludec”. Avances en Diabetologia 29 (2013): 4-11.
2. Muñoz M. “Degludec, una nueva insulina basal de acción ultra-lenta para el tratamiento de la diabetes tipo 1 y 2: avances en investigación clínica”. Endocrinología y Nutrición 61 (2014): 153-159.
3. Vora J., et al. “Clinical use of insulin degludec”. Diabetes Research and Clinical Practice 109 (2015): 19-31.
4. Berard L and MacNeill G. “Insulin degludec, a long-acting-daily basal analogue for type 1 and type 2 diabetes mellitus”. Canadian Journal of Diabetes 39 (2015): 4-9.
5. Yamamoto C., et al. “Degludec is superior to glargine in terms of daily glycemic variability in people with type 1 diabetes mellitus”. Endocrine Journal 63(2016): 53-60.
6. Heise T., et al. “Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of action”. Diabetes 8 (2016): 132-138.
7. Birkeland KI., et al. “Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine”. Diabetes Care 34 (2011): 661-665.
8. Sanhueza L., et al. “Experiencia con insulina degludec en pacientes diabéticos tipo 1 del Hospital San Juan de Dios, Santiago, Chile”. Revista Chilena de Endocrinología y Diabetes 10 (2017): 131-136.
9. Dzygalo K., et al. “The beneficial effect of insulin degludec on nocturnal hypoglycaemia and insulin dose in type 1 diabetic patients: a systematic review and meta-analysis of randomised trials”. Acta Diabetology 52 (2015): 231-238.
10. Lane W., et al. “Effect of degludec vs insulin glargine U100 on hypoglycemia in patients with type 1 diabetes. The SWITCH 1 randomized clinical trial”. JAMA 318 (2017): 33-44.
11. Vora J., et al. “Insulin degludec versus Insulin Glargine in type 1 and type 2 Diabetes Mellitus: A Meta-Analysis of Endpoints in Phase 3a Trials”. Diabetes Therapy 5 (2014): 435-446.
12. Heller S., et al. “Insulin Degludec, an ultra-long-acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal Bolus Type1): A phase 3, randomised, open-label, treat-to-target, non-inferiority trial”. Lancet 379 (2012): 1489-1497.
13. Nakae R., et al. “Medium-Term “Effects of Insulin Degludec on Patients with Type 1 Diabetes Mellitus”. Drugs 14 (2014): 133-138.
14. Ratner RE., et al. “Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials”. Diabetes, Obesity and Metabolism 15 (2013): 175-184.
15. Gold AE., et al. “Frequency of severe hypoglycemia in patients with type 1 diabetes with impaired awareness of hypoglycemia”. Diabetes Care 17 (1994): 697-703.
16. Koehler G., et al. “Insulin degludec is not associated with a delayed or diminished response hypoglycemia compared with insulin glargine in type 1 diabetes: a double-blind randomized crossover study”. Diabetologia 47 (2014): 40-49.
17. Home PD., et al. “Improved health status with insulin degludec compared with insulin glargine in people with type 1 diabetes”. Diabetes Medicine 29 (2012): 716-720.
18. Woodward A., et al. “Nocturnal hypoglycemia in type 1 diabetes-frecuency and predictive factors”. QJM 102 (2009): 603-607.
19. Lane W., et al. “Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients with Type 1 Diabetes. The SWITCH 1 Randomized Clinical Trial”. JAMA 318 (2017): 33-44.
20. Karamat MA., et al. “Clinical and Cost Implications of Insulin Degludec in Patients with Type 1 Diabetes and Problematic Hypoglycemia: A Quality Improvement Proyect”. Diabetes Therapy 9 (2018): 839-849.
21. Pollock RF and Tikkanen CK. “A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark”. Journal of Medical Economics 20 (2017): 213-220.